Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine.
OBJECTIVE
To determine the intestinal disposition mechanisms of paeoniflorin, a bioactive glucoside, and to investigate the mechanisms by which sinomenine increases paeoniflorin bioavailability.


METHODS
A single-pass "four-site" rat intestinal perfusion model and a cultured Caco-2 cell model were employed.


RESULTS
In both model systems, paeoniflorin permeability was poor. In the perfusion model, maximal absorption and metabolism of paeoniflorin occurred in duodenum and jejunum, which were significantly decreased by a glucosidase inhibitor gluconolactone (20 mM). On the other hand, paeoniflorin absorption in terminal ileum increased significantly but its metabolism did not in the presence of sinomenine and cyclosporine A. In the Caco-2 cell model, paeoniflorin was transported 48-fold slower than its aglycone (paeoniflorigenin). Absorptive transport of paeoniflorin was significantly (p < 0.05) increased by sinomenine (38%), verapamil (27%), and cyclosporine A (41%), whereas its secretory transport was significantly (p < 0.01) decreased by sinomenine (50%), verapamil (35%) and cyclosporine A (37%). In contrast, MRP inhibitors MK-571 and leukotriene C4 did not affect transport of paeoniflorin. Lastly, sinomenine was also shown to significantly increase the absorptive transport of digoxin (a prototypical p-glycoprotein substrate) and to significantly decrease its secretory transport.


CONCLUSIONS
Poor permeation, p-gp-mediated efflux, and hydrolysis via a glucosidase contributed to the poor bioavailability of paeoniflorin. Sinomenine (an inhibitor of the p-gp-mediated digoxin efflux) increased paeoniflorin's bioavailability via the inhibition of p-gp-mediated paeoniflorin efflux in the intestine.
Liu
Zhong Qiu
ZQ
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas 77030, USA.
Jiang
Zhi Hong
ZH
Liu
Liang
L
Hu
Ming
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001565:Benzoates / Q000032:analysis / Q000493:pharmacokinetics*; D001682:Biological Availability; D001692:Biological Transport / Q000502:physiology; D001952:Bridged-Ring Compounds / Q000032:analysis / Q000493:pharmacokinetics*; D018938:Caco-2 Cells; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D004077:Digoxin / Q000032:analysis; D004347:Drug Interactions; D005960:Glucosides / Q000032:analysis / Q000493:pharmacokinetics*; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D008297:Male; D039821:Monoterpenes; D009019:Morphinans / Q000032:analysis / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D006027:Glycosides
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001565:Benzoates; D001952:Bridged-Ring Compounds; D004077:Digoxin; D005960:Glucosides; D039821:Monoterpenes; D009019:Morphinans; C015423:peoniflorin; D006027:Glycosides; C009271:sinomenine